Trial Profile
A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2020
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Everolimus (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 27 Sep 2020 Status changed from completed to discontinued.
- 16 Jun 2017 Status changed from active, no longer recruiting to completed.
- 18 May 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov